Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of an experimental 20% betulinic acid ointment (BA ointment) as a treatment for dysplastic nevi with the potential to transform into melanoma.


Clinical Trial Description

Approximately 200 patients may be enrolled and screened in order to find twenty-eight (28) patients who qualify to be involved in this research at UIC. Dysplastic melanocytic nevus (DMN) is a histopathologic term implying a disordered proliferation of melanocytes associated with discontinuous and variable cellular atypia. DMN is graded into mild, moderate, and severe based on standard histological criteria. DMN is considered to be a likely precursor for melanoma, and individuals with DMN often have multiple instances of it scattered over their trunk and extremities. For this study, only DMN where the dysplasia is either moderate or severe will be included. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00346502
Study type Interventional
Source University of Illinois at Chicago
Contact
Status Withdrawn
Phase Phase 1/Phase 2
Start date January 2006
Completion date December 2015

See also
  Status Clinical Trial Phase
Terminated NCT04688749 - Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
Recruiting NCT00040352 - Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
Recruiting NCT04353050 - Atypical MOLes and Melanoma Early Detection Study (MoleMed) N/A